Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue by M. Urbini et al.
Oncotarget60036www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 36), pp: 60036-60045
Identification of SRF-E2F1 fusion transcript in EWSR-negative 
myoepithelioma of the soft tissue
Milena Urbini1, Annalisa Astolfi1, Valentina Indio1, Giuseppe Tarantino1, Salvatore 
Serravalle2, Maristella Saponara3, Margherita Nannini3, Alessandro Gronchi4, 
Marco Fiore4, Roberta Maestro5, Monica Brenca5, Angelo Paolo Dei Tos6, Gian Paolo 
Dagrada7, Tiziana Negri7, Silvana Pilotti7, Paolo Giovanni Casali8, Guido Biasco1, 
Andrea Pession1,2, Silvia Stacchiotti8 and Maria Abbondanza Pantaleo1,3
1 “Giorgio Prodi” Cancer Research Center, University of Bologna, Bologna, Italy
2 Pediatric Hematology and Oncology Unit, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
3 Department of Specialized, Experimental and Diagnostic Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, 
Bologna, Italy
4 Department of Surgery, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
5 Unit of Experimental Oncology 1, CRO Aviano National Cancer Institute, Aviano, Italy
6 Department of Anatomic Pathology, General Hospital of Treviso, Treviso, Italy
7 Department of Diagnostic Pathology and Laboratory, Laboratory of Experimental Molecular Pathology, Fondazione IRCCS 
Istituto Nazionale Tumori, Milan, Italy
8 Cancer Medicine Department, Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Fondazione IRCCS 
Istituto Nazionale Tumori, Milan, Italy
Correspondence to: Maristella Saponara, email: maristella.saponara@unibo.it
Keywords: myoepithelial neoplasm; SRF; E2F1; fusion; sarcoma
Received: April 05, 2017 Accepted: May 01, 2017 Published: May 17, 2017
Copyright:  Urbini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Myoepithelial neoplasms (MN) are rare and not well-circumstanced entities 
displaying a heterogeneous spectrum of genetic abnormalities, including EWSR1, FUS 
and PLAG1 rearrangements. However, in the remaining MN no other fusion gene has 
been described and knowledge concerning secondary acquired molecular alterations is 
still poor. Therefore, we screened 5 cases of MN of the soft tissue by RNA sequencing 
with the aim of identifying novel fusion transcripts.
A novel SRF-E2F1 fusion was detected in two cases: one was negative for other 
fusions while the other showed also the presence of FUS-KLF17. The fusion was 
validated through independent techniques and, in both cases, SRF-E2F1 was detected 
only in a subclone of the tumoral mass. SRF-E2F1 maintained the coding frame, thus 
leading to the translation of a chimeric protein containing the DNA-binding domain 
of SRF and the trans-activation domain of E2F1. Moreover, ectopical expression of 
SRF-E2F1 demonstrated that the chimeric transcript is functionally active and could 
affect tumor growth.
Occurrence in two cases and biological relevance of the two genes involved 
suggest that the SRF-E2F1 fusion might become a helpful diagnostic tool. Further 
biologic studies are needed to better assess its role in MN biology.
INTRODUCTION
Myoepithelial neoplasms, namely mixed tumor, 
myoepithelioma (ME) and malignant myoepithelioma/
myoepithelial carcinoma (MME), are rare and not well 
circumstanced entities having similarities to salivary gland 
counterparts [1] described in soft tissue, skin, bone, breast, 
kidney [2], thoracic region [3] and vulvar region [4]. The 
pathologic and molecular characteristic of MN have been 
better defined only in the last few years. 
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Given the rarity, the heterogeneous morphology, 
the poorly informative immunophenotype and the lack 
of well-defined prognostic criteria, this entity poses 
diagnostic and clinical challenges. In particular, MN 
needs to be distinguished from extraskeletal myxoid 
chondrosarcoma, ossifying fibromyxoid tumors [5], 
myxoinflammatory fibroblastic sarcoma, chordoma [6], 
poorly differentiated synovial sarcoma and Ewing sarcoma 
[7].
Detection of specific fusion transcripts can help 
to better identify MN and to discriminate them from 
other entities. According to the literature, nearly half of 
myoepithelial neoplasm carries EWSR1 translocations to 
an ever increasing variety of partners [5, 8]. EWSR1 is 
one of the most commonly involved genes in sarcoma 
translocations. In addition to ME, this gene has been found 
fused with several distinct partners in a variety of different 
tumors, including Ewing’s sarcoma, extraskeletal myxoid 
chondrosarcoma, myxoid liposarcoma and others [1, 9]. 
In addition to EWSR1, also PLAG1 translocations have 
been described in MN cases with ductal differentiation 
[10]. Other fusion events were identified in a small subset 
of myopithelial tumors (6.3%) involving the FUS gene 
[11]. In the remaining fraction of MN, the driver genetic 
alteration has not been identified yet. Moreover, the role 
of gene fusions in MN progression remains to be defined. 
In 2013, we started an Italian multi-institutional 
collaboration among centers dedicated to sarcoma with the 
aim of better defining MN molecular profile. Within this 
project, still ongoing, we performed whole transcriptome 
sequencing in five cases, four ME and one MME, to 
discover novel fusion events.
RESULTS
Fusion events prediction
Whole transcriptome sequencing was performed 
on five tumors: four primary ME and one metastatic 
MME of the soft tissues (for details see Table 1). 
Three bioinformatic tools were used for prediction and 
identification of fusion transcripts. In the two EWSR1 
positive ME tumors it was possible to identify the partners 
of the fusion: NFATC2 in one case and PBX3 in the 
other. No additional fusion event was detected in these 
two patients. Instead, the FUS positive case (L108) was 
predicted to carry a fusion between SRF and E2F1, besides 
the primary chimeric transcript involving FUS and KLF17 
genes. The same SRF-E2F1 chimera was also detected in 
one fusion-negative tumor, L107 (Table 2). All fusion 
transcripts, either known or novel, were validated by RT-
PCR of the breakpoint followed by Sanger sequencing and 
FISH. 
Characterization of the novel SRF-E2F1 fusion
The SRF-E2F1 chimeric transcript was shown to 
be highly expressed in sample L107, as suggested by the 
amount of supporting reads (respectively 338 splitted and 
632 spanning reads across the junction), while it was less 
represented in the FUS-KLF17 positive sample (5 split and 
25 spanning reads) (Table 2).
SRF-E2F1 was predicted to retain the first 100 
bases of the third intron of SRF joined with the second 
half of exon 5 of E2F1, exactly 66 bases after the original 
splice acceptor site (Figure 1A). Despite the complex 
breakpoint, with the joining of SRF intron with E2F1 exon 
5, the fusion transcript maintained the coding frame, thus 
leading to the translation of a putative chimeric protein. 
The predicted SRF-E2F1 fusion protein retains the MAD 
box domain of SRF and the trans-activation domain of 
E2F1, suggesting that the chimeric protein retains the 
DNA binding specificity of SRF while adding the trans-
activation activity of E2F1 (Figure 1B). 
In both L107 and L108, SRF and E2F1 exons 
involved in the fusion gene were highly expressed when 
compared to the ones not participating in the chimera 
(Figure 2). These data suggest that most of SRF and E2F1 
expression in these samples are derived from the fusion 
transcript rather than from the uninvolved alleles.
In order to identify the genomic breakpoint, we 
performed PCR amplification also on genomic DNA 
extracted from the two tumor tissues. PCR amplification of 
the breakpoint region yielded a PCR product of different 
size in the two samples, about 300bp for L107 and about 
200bp for L108. Sanger sequencing of these amplicons 
revealed that, in both samples, the genomic breakpoint 
matched exactly with the SRF-E2F1 junction detected at 
transcriptional level. In L108 a genomic deletion occurred 
downstream the breakpoint, involving entirely intron 
5 (95bp) and the first 9 bases of exon 6 of E2F1, thus 
leading to the shorter amplicon while keeping the coding 
frame of E2F1 (see supplementary File 2). 
Then, we performed a FISH break-apart assay 
on the SRF and FUS loci to support the presence of the 
rearrangements through an independent technique and to 
analyze the clonality of the fusion events (Figure 3A, 3B). 
In both L107 and L108, corresponding to one spindle cell 
and one mixed type myoepithelioma respectively (Fig. 
3C), the rearrangement of SRF gene was observed in about 
20% of tumor cells. Interestingly, in L108 it was also 
possible to see the subclonality of this event: while the 
SRF rearrangement was observed only in a subpopulation 
of the cells, FUS rearrangement was observed in almost 
all tumor cells (92%). Moreover, concomitant presence 
of both SRF and FUS rearrangements were observed in 
the same cell, as shown by re-hybridizing SRF FISH slide 
with the FUS break apart probe. Interestingly, the two 
SRF-E2F1 positive patients were younger than the other 
three cases with a mean age at diagnosis of 29.5 vs 45.3 
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Table 1: Clinical characteristic
Pt ID Gender
Age at 
disease 
(years)
Site of 
primary 
tumor
Diagnosis Molecular event
Primary 
tumor 
treatment
Local 
recurrence 
(Y/N)
Distant 
recurrence (Y/N)
Disease 
free 
survival 
(months)
Status
last 
follow-up
Overall 
survival 
(months)
L107 F 33 iliac region spindle cell myoepithelioma Unknown CSR N N 7 NED 7
L108 M 26 right foot myxed type FUS translocated LP + CSR N N 60 NED 60
L138 M 43 right arm malignant myoepithelioma Unknown
CHT + LP + 
CSR Y Y (lung) 1 DOD 9
L161 M 47 right foot spindle cell myoepithelioma
EWSR1 
translocated CSR Y Y (lymphonodes) 110 NED 324
L162 F 46 Left leg
Myxed type 
with focal ductal 
differentiation
EWSR1 
translocated CSR N N 54 NED 54
CSR = complete surgical resection, LP= limb perfusion; CHT= Neo-adjuvant CHT
Table 2: List of fusion events identified by three bioinformatics predictors: Defuse (Df), ChimeraScan (ChS) and 
FusionMap (FsM). 
Pt ID 5’gene Breakpoint position 5’gene 3’gene
Breakpoint position 
3’gene Splitted reads Spanning reads Frame Prediction tool
L107 SRF 6:43143805 E2F1 20:32265281 338 632 yes Df, ChS, FsM
L108
SRF 6:43143805 E2F1 20:32265281 5 25 yes Df, ChS, FsM
FUS 16:31198157 KLF17 1:44592015 - 12 yes ChS
L138 none - none - - - - -
L161 EWSR1 22:29684775 PBX3 9:128697751 6 43 yes Df, ChS, FsM
L162 EWSR1 22:29678546 NFATC2 20:50133494 yes ChS, FsM
Figure 1: SRF-E2F1 fusion transcript identified by whole-transcriptome sequencing. A. Schematic representation of SRF-
E2F1 chimeric transcript showing the exact breakpoint sequence identified and validated by Sanger sequencing. B. Schematic representation 
of the protein domains involved in the putative chimeric protein.
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years (P < 0.05), even if the cohort analyzed was too small 
to draw any definitive conclusion.
We then searched, through whole exome sequencing, 
the presence of other genomic aberrations in the two SRF-
E2F1 positive cases. No relevant copy number alteration 
was identified. A mean of 11 somatic mutations were 
detected, no recurrently altered gene was present and all 
mutations were classified as passenger (Supplementary 
File 3).
Finally, to assess if SRF-E2F1 could be functionally 
active, the fusion gene was cloned into a plasmid 
vector and expressed in HEK293 cell lines (Figure 4A). 
Expression of the fusion protein led to a marked up-
regulation of EGR1 and FOS (Figure 4B), two genes 
target of SRF transcriptional regulation [12], and to a 
significative increase of cell growth rate with respect to 
negative controls (22%) (Figure 4C), including a scramble 
SRF-E2F1 chimera carrying a premature stop codon. 
DISCUSSION
In this work, we reported the identification of a 
fusion event involving SRF and E2F1 genes in two MN 
of the soft tissues. This event was detected in one FUS-
KLF17-translocated ME tumor and in one ME negative for 
Figure 2: Validation of SRF-E2F1 fusion in L107 and L108 ME tumors. Normalized reads count showing higher expression 
of SRF and E2F1 exons involved in the fusion. In the two larger panels are represented the normalized reads count, respectively in blue for 
L107 and in red for L138, a sample used as control without SRF-E2F1 fusion. In the two box-plot are represented the average expressions 
of SRF and E2F1 exons before (5’) and after (3’) the breakpoint in both L107 and L108. 
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fusion transcripts involving either EWSR1 or FUS, both 
lacking pathological evidence of malignancy according to 
the criteria outlined in Jo et al [1]. In both tumors, the 
translocation appeared to be subclonal thus suggesting that 
it could be acquired over time.
Myoepithelial neoplasms of the soft tissues are very 
rare tumors characterized in the late ’90 that have been 
recently classified by C. Fletcher into 3 different groups 
called mixed tumor, myoepithelioma and malignant 
myoepithelioma/myoepithelial carcinoma [1]. This 
Figure 3: FISH analysis on thawed frozen tumor specimens. A. FISH analysis for the SRF gene on thawed frozen tumor 
specimens of L107 and L108: fusion positive cells showed one orange/green fusion, one orange, and one green signal pattern indicative 
of a rearrangement of one copy of the SRF gene. B. FISH analysis for the FUS gene on thawed frozen tumor specimen of L108: fusion 
positive cells showed a signal pattern consisting of one orange/green fusion signal, one orange signal, and a separate green signal indicates 
one normal 16p11.2 locus and one 16p11.2 locus affected by a FUS translocation. C. Pathologic findings on the two SRF-E2F1 positive 
cases: L107 showed a myoepithelioma comprised of predominantly  myoepithelial spindle cells; L108 showed an area of epithelioid cells 
arranged in nested pattern and embedded in myxoid-hylinized stroma in an otherwise mixed myoepithelioma (not shown).
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family of neoplasms described at different anatomic sites 
[2-4] are marked by a high degree of heterogeneity with 
respect to both the morphologic and the molecular clues. 
Furthermore, it is still not completely clear to which extent 
MN arising from different locations do represent the same 
entity and only little data are currently available in both 
MN natural history and sensitivity to medical agents. 
It is well known that gene fusions are a relevant class 
of “driver mutations” in cancer, particularly in hematologic 
malignancies and in a subset of sarcomas. Several fusion 
transcripts had been detected in MN, involving EWSR1, 
PLAG1 and FUS [5, 10, 11, 13], however for a significant 
portion of this tumors no fusion event have been identified 
and, to date, no reports of secondary acquired fusion genes 
in this disease are available. The involvement of fusion 
genes in MN progression is poorly defined.
Here, we report a novel fusion event, consisting in 
a SRF-E2F1 fusion in two cases of soft tissue ME, one 
mixed type tumor and one spindle cell myoepithelioma, 
respectively. Interestingly, the two SRF-E2F1 positive 
patients were younger respects to the other three cases, 
however the cohort analyzed was too small to draw a 
definite conclusion. Moreover, excluding the fusion genes 
identified, no other relevant alterations were detected 
through genomic analysis, revealing a generally normal 
karyotype with few passenger mutations. SRF-E2F1 
is a complex fusion that originates from a balanced 
translocation between chr6 and chr20. Even if the 
breakpoint was located between the middle of intron 3 
of SRF and the middle of exon5 of E2F1, the predicted 
chimeric protein retained the coding frame and the critical 
domains of both proteins. It is not infrequent to detect 
fusion genes with complex breakpoints similarly to the 
cases described here, for example some forms of BCR-
ABL could have the fusion junction located within coding-
exons or could contain intronic regions while maintaining 
the reading frame [14].
SRF encodes a MADS-box transcription factor 
that, through the binding to CArG box motifs, controls 
the expression of a wide set of genes including immediate 
Figure 4: SRF-E2F1 expression in HEK293 cell line. A. RT-PCR showing SRF-E2F1 mRNA expression in HEK293 cells, 72h 
after transfection with SRF-E2F1 plasmid. Mock (lipofectamine only) and pcDNA3.1 (empty vector) transfected samples are shown 
as negative controls. B. mRNA relative expression of EGR1 and FOS, two genes target of SRF, 72h after transfection. Fold changes 
were evaluated in comparison to untreated sample. GAPDH and GUSB were used as housekeeping genes. P value was estimated against 
pcDNA3.1 and Scramble using t-test (*p < 0.05; **p < 0.01). C. HEK293 relative cell growth evaluated using WST1 assay, 72h after 
transfection. SRF-E2F1 transfetcted cells showed a significant (***p < 0.001) increase of cell growth in comparison with both scramble 
and pcDNA3.1 treated cells. P-value was estimated with t-test.
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early genes, like c-Fos, Jun and Egr, as well as tissue-
specific genes involved in cell proliferation, migration, 
angiogenesis cytoskeletal organization, energy 
metabolism and myogenesis [12, 15, 16]. Accumulating 
evidence suggested that SRF may play multiple roles in 
carcinogenesis and tumor progression in various cancers, 
specifically in the mesenchymal transition of epithelial 
tumor cells [17-19]. Recently, fusion genes involving SRF 
were detected in some types of mesenchymal tumors, 
including SRF-NCOA2 in one case of infantile spindle 
cell rhabdomyosarcoma [20] and SRF-RELA in 7 cases of 
myofribroma and myopericytoma [21]. On the other side, 
E2F1 belongs to the E2F family of transcription factors 
that is involved in cell cycle progression and apoptosis 
induction in response to DNA damage [22]. E2F1 plays a 
critical role in the malignant phenotypes of some cancers. 
Yet, deregulation of E2F1 expression can either promote 
or inhibit tumorigenesis depending on the nature of the 
cellular context [22, 23]. 
To our knowledge, fusion events involving E2F1 
has not been previously reported in tumors, however 
several chimeric proteins has been designed and tested 
in vitro for functional studies. In particular, it was shown 
that the acidic activation domain of E2F1, located near the 
C-terminus of the protein, is able to function even when 
attached to the DNA-binding domain of a heterologous 
protein [24, 25]. Herein, we demonstrated that the 
expression of SRF-E2F1 fusion gene produced a chimeric 
protein functionally active. The role of this novel fusion 
protein is left to be clarified. However, even if preliminary, 
these results indicated that the chimeric protein could 
retain DNA binding specificity of SRF and through the 
trans activation domain of E2F1 is able to activate SRF 
target genes, probably supporting tumor growth.
Although SRF-E2F1 was confirmed both at 
transcriptional and at genomic level, only a subclone of 
the tumors carried the genomic translocation as shown 
by FISH. Moreover, the concomitant presence of two 
fusion events in one tumor sample (SRF-E2F1 and FUS-
KLF17 in sample L108), suggests that ME could have 
heterogeneous composition, with expansion of several 
clones and accumulation of secondary alterations. 
Together, these data suggest that SRF-E2F1 fusion 
could be a secondary event acquired during tumor clonal 
genetic evolution. Whether the SRF-E2F1 clone has 
the potentiality of expansion to become the prevalent 
component of the tumor, thus affecting patient outcome, 
remains to be elucidated. 
This cytogenetic abnormality might become a 
helpful diagnostic tool and further biologic studies 
are needed to elucidate its role in MN. The biological 
relevance of the two genes involved and the fact that this 
event was found to occur in two different patients, suggest 
that SRF-E2F1 fusion could be relevant in the tumor 
natural history, being a late event in the tumor biology 
time course. It certainly warrants further investigations 
across larger series. 
In conclusion, MN are characterized by an extreme 
heterogeneity in morphological immunohistochemical and 
genetic features. In particular, an ever increasing number 
of different gene fusions is reported in this entity. Here 
we describe an intra-tumoral heterogeneity which adds a 
further layer of complexity and suggests that ME could 
bear multiple driving events, among which different gene 
fusions.
MATERIALS AND METHODS
Case selection
Cases were selected among those operated from 
2012 at Fondazione IRCCS Istituto Nazionale Tumori, 
Milan, Italy, for primary tumor, with diagnosis of 
MN, arising from the soft tissue, whose fresh/frozen 
tumor tissue adequate for the analysis was available. 
Diagnosis was confirmed by sarcoma expert pathologists 
(SP; APDT). Whole transcriptome sequencing of 
tumor samples was performed at “Giorgio Prodi” 
Interdepartmental Center of Cancer Research, University 
of Bologna, Italy. 
This study was approved by the local Ethical 
Committee of all the involved Institutions.
Patients and tumor samples
Fresh tissue specimens of five cases of soft tissue 
MN (2 EWSR positive; 1 FUS positive; 2 negative for 
EWS, FUS, NR4A3 and PLAG1) were collected snap-
frozen in liquid nitrogen and stored at -80°C until analysis. 
Patient characteristics are listed in Table 1.
Whole-transcriptome sequencing
Total RNA was isolated from fresh frozen tumor 
tissues using the RNeasy spin-column method (Qiagen, 
Milan, Italy). Whole-transcriptome RNA libraries 
were prepared in accordance with Illumina’s TruSeq 
RNA Sample Prep v2 protocol (Illumina, San Diego, 
California). Briefly, poly(A)-RNA molecules from 500 
ng of total RNA were purified using oligo-dT magnetic 
beads. Following purification, the mRNA was fragmented 
and randomly primed for reverse transcription followed 
by second-strand synthesis to create double-stranded 
cDNA fragments. These cDNA fragments went through a 
terminal-end repair process and ligation using paired-end 
sequencing adapters. The products were then amplified 
to enrich for fragments carrying adapters ligated on both 
ends and to add additional sequences complementary 
to the oligonucleotides on the flow cell, thus creating 
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the final cDNA library. 12pM paired-end libraries were 
amplified and ligated to the flowcell by bridge PCR, 
and sequenced at 2x75bp read length, using Illumina 
Sequencing by synthesis technology. An average of 77 
million reads were obtained for whole transcriptome 
analysis. Reads were mapped on the human reference 
genome by TopHat/BowTie pipeline. For gene fusions 
discovery, three bioinformatics tools were used: DeFuse, 
ChimeraScan, and FusionMap. For gene expression 
evaluation, normalized read counts were determined for 
each coding position of SRF and E2F1 mRNA, then the 
ratio between average expressions of exons before and 
after breakpoint was calculated for each genes.
Fusion validation
500ng of total RNA was retrotranscribed to 
cDNA using First Strand cDNA Sythesis kit (Roche) 
and oligo-dT primers, then the fusion transcript 
was amplified using primers pair specific for the 
breakpoint region. Additionally, amplification of 
the breakpoint was performed also on tumor DNA. 
After quality check on agarose gel, amplicons were 
purified and sequenced using the Sanger method. 
The primers pairs used to amplify and sequence the 
fusion transcripts of interest were: SRF_exon3_Fw 
5’-TCACCAACTACCTGGCACCA-3’ and E2F1_exon6_
Rev 5’-ACATCGATCGGGCCTTGTTT-3’; FUS_ex6_Fw 
5’- GCTATGGACAGCAGGACCGT - 3’ and KLF17_
ex2_Rev 5’- GCTGTGAGGAAAGTGCTGAATG -3’ 
FISH
FISH analysis was performed on frozen tumor 
tissue imprints to confirm rearrangements of the SRF and 
FUS genes, using two SRF specific BlueFISH probes 
(BlueGnome Ltd., Cambridge) and the ZytoLight SPEC 
FUS Dual Color Break Apart Probe (ZytoVision GmbH, 
Germany). In detail, for the SRF gene, two BAC clones 
partially overlapping on the SRF gene: RP11-387M24 
(extending towards 3’ end) and RP11-480N24 (extending 
towards 5’end), labelled in red and green respectively, 
were used. 
Whole exome sequencing
Genomic DNA was extracted from fresh-frozen 
tumor specimens and from matched PB with QiAmp 
DNA mini kit (Qiagen). Libraries were synthesized with 
Nextera Rapid Capture Exome Kit (Illumina) following 
manufacturer’s recommendations. Reads were mapped 
with BWA and GATK and Mutect were used to call the 
Ins/del variants and Single nucleotide variants. Somatic 
mutations were identified by verifying the presence of 
alternate allele in the normal counterpart. All variants were 
filtered in order to select novel or rare events (databases: 
dbSNP, 1000Genomes, ExAC and EVS) and their effect 
on protein structure and function was predicted with 
SNPeff. Moreover, copy number analysis (detection of 
large amplifications or deletions) was performed making 
a consensus between two softwares (Control FREEC and 
ADTEX) with paired tumour/matched normal samples. 
Variations was filtered also on the polymorphic copy 
number variants from the Database of human Genomic 
Variants.
Cloning and transfection of SRF-E2F1 in HEK293 
cell line
The entire coding sequence of SRF-E2F1 fusion gene 
was amplified from cDNA of L107 using the following 
primers: SRF_Fw 5’-CGCCATGTTACCGACCCAA-3’ 
and E2F1_Rev 5’- AGAGACAAGGTGAGCATCTCTGG 
-3’. The amplicon was then cloned into a plasmid 
vector using pcDNA3.1 TOPO TA Expression kit (Life 
Technologies). Plasmid DNA of several clones were 
checked for insert orientation and for mutations through 
Sanger sequencing. Two clones, one containing an intact 
SRF-E2F1 and a second one with a premature stop codon 
(scramble SRF-E2F1), were selected for subsequent 
transfection experiments (see supplementary File 1 for 
scramble sequence). HEK293 cell line were grown on 
DMEM medium with 10% of foetal bovine serum, 1% 
L-glu and 1% pen-strep. Cells were transfected with 
SRF-E2F1, scramble or empty pcDNA3.1 vector using 
Lipofectamine 2000 (Life Technologies). Cells untreated 
and mock (treated with only Lipofectamine) were used as 
controls. Total RNA was extracted 72h after transfection, 
and fusion gene expression was evaluated with RT-
PCR. mRNA expression level of EGR1 and FOS were 
evaluated in with realtime PCR (LightCycler480, Roche). 
To determine the proliferation activity, transfected cells 
were seeded in triplicate in a 96well plate (10.000 cell/
well) and WST1 assay (Roche) was performed 72h 
after transfection. These experiments were repeated in 
triplicate. Relative cell growth rate was calculated in 
comparison with scramble and pcDNA3.1 treated cells. 
GraphPad PRISM Software was used for graph design and 
statistical analysis.
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